PureCycle Technologies, Inc. Q1 FY2025 earnings call

• Significant progress in the first quarter with first reported revenues. Onstream time at Ironton improved, achieving almost 90% onstream time in April, a major improvement from prior years.
• Commercial efforts: engaged in over 30 trials, 24 in industrial stage with potential product sales over 300 million pounds. Trials in rigid packaging increased, with 13 in industrial phase vs. 5 prior quarter. Conversations with large auto OEMs and interest due to 2030 recycled content regulations.
• Compounding strategy: PureFive Ultra and PureFive Choice products, with film (BOPP) showing success in trials, accelerating plans for significant contribution to sales in second half. Ironton produced 4.3 million pounds of resin with 14 million pounds of inventory.
• Learnings from Ironton to scale technology for higher capacity, reducing CapEx and OpEx, with plans to build larger future facilities based on these learnings.

The company reported its first revenues in history. Operations at Ironton produced 4.3 million pounds of resin with approximately 14 million pounds of inventory. Compounding strategy involves PureFive Ultra (flagship nearly virgin-indistinguishable product) and PureFive Choice (blended products for various applications like film, fiber, automotive). The compounding strategy allows expanding sales volumes beyond Ironton's nameplate capacity and improves unit economics per pound of PCT material.

• 2025 is a transformative year with revenue ramp expected in the second half. Confidence in achieving sales goals with growing trials and customer interest. Scaling future facilities based on Ironton learnings to drive capital and operational efficiencies, improving profitability and return on capital.
• Expectations to see progress in commercial trials moving from pilot to industrial and ramp in the second half of 2025.

• Known and unknown risks and uncertainties, including those in Safe Harbor Provisions, where actual results may differ materially from preliminary estimates. Risks related to changes in quarter end and year-end adjustments, supply chain, and market adoption of new products.

Q: Please explain the strategy regarding the 14 million pounds of inventory.

A: As customer trials proceeded faster than expected and early realized pricing from fiber sales, the company decided to hold back inventory for higher value sales in the second half of the year.

Q: Can you provide more color on growth plans related to the second facility?

A: Learnings from Ironton on reliability and technology understanding enable scaling to much larger plants, lowering CapEx and OpEx, with plans to build larger future facilities in regions with high demand, leveraging customer interest and recycled content regulations.

Q: How is the progress of trials from Q4 2024 to Q1 2025?

A: There has been continued progress with trials, with 2025 being a transformative year, showing good progress across customer trials and optionality in allocating Ironton production.

Q: What's the pricing structure outlook?

A: Still sticking to expected ASP, with feedstock plus pricing gaining traction due to supply-demand imbalance and market dynamics, being the most logical approach for the specialty recycled product.

Q: Where are the trials in terms of progression and timeline?

A: Trials continue to progress, with some starting to commercialize in Q2 and second half of 2025 looking positive. Compounding is seen as a service enabling quicker qualifications and flexibility with customers.

Q: Any impediments to trials and timeline?

A: Every customer has different requirements and timelines, but continued good performance in trials provides optionality, with progress expected in 2025 towards commercialization.